MXPA01011344A - El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. - Google Patents
El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.Info
- Publication number
- MXPA01011344A MXPA01011344A MXPA01011344A MXPA01011344A MXPA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A
- Authority
- MX
- Mexico
- Prior art keywords
- tyrosine kinase
- protein tyrosine
- prophylactic
- kinase pathway
- therapeutic treatment
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title abstract 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000037361 pathway Effects 0.000 title abstract 4
- 208000022873 Ocular disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 7
- 230000000069 prophylactic effect Effects 0.000 abstract 5
- 230000001225 therapeutic effect Effects 0.000 abstract 5
- 241001465754 Metazoa Species 0.000 abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 3
- 208000002780 macular degeneration Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 210000001775 bruch membrane Anatomy 0.000 abstract 2
- 210000003161 choroid Anatomy 0.000 abstract 2
- 230000007850 degeneration Effects 0.000 abstract 2
- 210000001525 retina Anatomy 0.000 abstract 2
- 206010025421 Macule Diseases 0.000 abstract 1
- 229940045109 genistein Drugs 0.000 abstract 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 abstract 1
- 235000006539 genistein Nutrition 0.000 abstract 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
La presente invencion esta dirigida a un metodo para el tratamiento profilactico y terapeutico de la degeneracion macular relacionada con la edad asi como a metodos para el tratamiento profilactico y terapeutico de las complicaciones exudativas y atroficas de la degeneracion macular relacionada con la edad. Los metodos implican la administracion de un inhibidor de la ruta de la proteina tirosina quinasa a un animal, tal como un mamifero, en particular un humano, en una cantidad suficiente para tratar al animal respecto a la degeneracion macular relacionada con la edad o a una complicacion exudativa o atrofica de la misma, respectivamente, en forma profilactica o terapeutica. La presente invencion provee tambien un metodo para el tratamiento profilactico y terapeutico de la degeneracion de la retina, un metodo para el tratamiento profilactico y terapeutico de la degeneracion de la coroide y un metodo para el tratamiento profilactico y terapeutico del engrosamiento de la membrana de Bruch. Estos metodos implican la administracion de un inhibidor de la ruta de la proteina tirosina quinasa a un animal, tal como un mamifero, en particular un humano, en una cantidad suficiente par tratar la macula, retina, coroide o membrana de Bruch, respectivamente, en forma profilactica o terapeutica. De preferencia el inhibidor de la ruta de la proteina tirosina quinasa es genisteina o un analogo o profarmaco de la misma o una sal farmaceuticamente aceptable de cualquiera de los anteriores.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13311299P | 1999-05-07 | 1999-05-07 | |
| US35044099A | 1999-07-09 | 1999-07-09 | |
| PCT/US2000/012339 WO2000067738A2 (en) | 1999-05-07 | 2000-05-05 | The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01011344A true MXPA01011344A (es) | 2004-06-03 |
Family
ID=26831056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA01011344A MXPA01011344A (es) | 1999-05-07 | 2000-05-05 | El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1178791A2 (es) |
| JP (1) | JP4920134B2 (es) |
| AU (1) | AU774495B2 (es) |
| CA (1) | CA2373178C (es) |
| MX (1) | MXPA01011344A (es) |
| WO (1) | WO2000067738A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2826276A1 (fr) * | 2001-06-20 | 2002-12-27 | Raouf Rekik | Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| JP2009521493A (ja) * | 2005-12-23 | 2009-06-04 | アルコン，インコーポレイテッド | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 |
| US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
| US12035973B2 (en) | 2018-01-25 | 2024-07-16 | Osaka University | Method for detecting stressed state and stress detection apparatus |
| CN114931574A (zh) * | 2022-06-14 | 2022-08-23 | 深圳爱尔眼科医院 | 一种铁死亡抑制剂及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09316000A (ja) * | 1996-05-31 | 1997-12-09 | Toagosei Co Ltd | 血管新生抑制用ワクチン |
| EP0963200B9 (en) * | 1996-11-05 | 2005-11-30 | The Children's Medical Center Corporation | Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid |
| US5948815A (en) * | 1997-03-14 | 1999-09-07 | The Regents Of The University Of California | Methods for inhibiting bacterial cytotoxicity |
| WO1999016755A1 (en) * | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| EP1061913B1 (en) * | 1998-03-13 | 2007-06-27 | The Johns Hopkins University School Of Medicine | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy |
-
2000
- 2000-05-05 JP JP2000616765A patent/JP4920134B2/ja not_active Expired - Fee Related
- 2000-05-05 MX MXPA01011344A patent/MXPA01011344A/es active IP Right Grant
- 2000-05-05 WO PCT/US2000/012339 patent/WO2000067738A2/en active IP Right Grant
- 2000-05-05 AU AU49884/00A patent/AU774495B2/en not_active Ceased
- 2000-05-05 EP EP00932108A patent/EP1178791A2/en not_active Withdrawn
- 2000-05-05 CA CA2373178A patent/CA2373178C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1178791A2 (en) | 2002-02-13 |
| CA2373178C (en) | 2013-07-02 |
| AU774495B2 (en) | 2004-07-01 |
| JP4920134B2 (ja) | 2012-04-18 |
| JP2002544159A (ja) | 2002-12-24 |
| CA2373178A1 (en) | 2000-11-16 |
| AU4988400A (en) | 2000-11-21 |
| WO2000067738A3 (en) | 2001-08-23 |
| WO2000067738A2 (en) | 2000-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2321560A1 (en) | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation | |
| Gros | Spasticity—clinical classification and surgical treatment | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO1998010767A3 (en) | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders | |
| TW200833341A (en) | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | |
| CA2213833A1 (en) | Vascular endothelial cell growth factor antagonists | |
| MX9702349A (es) | Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma. | |
| EP2514420A3 (en) | Use of rapamycin for the treatment or prevention of age-related macular degeneration | |
| IL175875A0 (en) | Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon | |
| NO970517L (no) | Topiske oftalmiske formuleringer inneholdende doxepinderivater for behandling av öyenallergisykdommer | |
| EP1074258A3 (en) | Methods and compositions for treating diseases and conditions of the eye | |
| CA2262268C (en) | Method of treating impotence due to spinal cord injury | |
| BG105875A (en) | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy | |
| WO2002047673A3 (en) | Methods and compositions to treat conditions associated with neovascularization | |
| MXPA01011344A (es) | El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. | |
| ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
| MXPA03001160A (es) | Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico. | |
| EP1037622A4 (en) | TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS | |
| WO2005102303A3 (en) | Antiprostaglandins for the treatment of ocular pathologies | |
| IS8096A (is) | Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum | |
| EP1482922A4 (en) | AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS | |
| AU6418296A (en) | Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use | |
| WO1998024898A3 (en) | Therapeutic composition comprising the kal protein and use of the kal protein | |
| ATE325618T1 (de) | Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb | |
| MXPA04001255A (es) | Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |